Who are Dotarem®-enhanced MRI's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Gadavist, Gadobutrol (Gadovist/Gadavist), MultiHance 0.05 mmol/kg, gadoxetic acid enhanced liver MRI, Gadoteric Acid Meglumine Salt, Gadopentetate-Dimeglumine 0.05 mmol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dotarem-enhanced-mri.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dotarem®-enhanced MRI — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dotarem®-enhanced MRI (Dotarem®-enhanced MRI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Gadolinium-based contrast agent. Area: Diagnostic Imaging.

marketed Gadolinium-based contrast agent Water proton relaxation (T1 relaxation time) Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

Dotarem®-enhanced MRI (Dotarem®-enhanced MRI) — Guerbet. Dotarem is a gadolinium-based contrast agent that enhances MRI signal by altering the magnetic properties of nearby water molecules in tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Dotarem®-enhanced MRI TARGET	Dotarem®-enhanced MRI	Guerbet	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadavist	GADOBUTROL	Bayer	marketed	Gadolinium-based Contrast Agent [EPC]		2011-01-01
Gadobutrol (Gadovist/Gadavist)	Gadobutrol (Gadovist/Gadavist)	Insel Gruppe AG, University Hospital Bern	marketed	Gadolinium-based contrast agent (GBCA)	Water proton relaxation (T1 relaxation enhancement)
MultiHance 0.05 mmol/kg	MultiHance 0.05 mmol/kg	Bracco Diagnostics, Inc	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)
gadoxetic acid enhanced liver MRI	gadoxetic acid enhanced liver MRI	Seoul National University Hospital	marketed	Gadolinium-based contrast agent	Organic anion transporter 1B1/1B3 (OATP1B1/1B3)
Gadoteric Acid Meglumine Salt	Gadoteric Acid Meglumine Salt	The Central Hospital of Lishui City	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation time)
Gadopentetate-Dimeglumine 0.05 mmol	Gadopentetate-Dimeglumine 0.05 mmol	Paracelsus Medical University	marketed	Gadolinium-based contrast agent	Water protons (T1 relaxation enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Gadolinium-based contrast agent class)

Guerbet · 4 drugs in this class
Bayer · 4 drugs in this class
Paracelsus Medical University · 2 drugs in this class
GE Healthcare · 1 drug in this class
Bracco Diagnostics, Inc · 1 drug in this class
Seoul National University Hospital · 1 drug in this class
Shanghai Shengdi Pharmaceutical Co., Ltd · 1 drug in this class
The Central Hospital of Lishui City · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dotarem®-enhanced MRI — Competitive Intelligence Brief. https://druglandscape.com/ci/dotarem-enhanced-mri. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing